Bacillus subtilis IAB/BS03 Strain for Plant Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Bacillus subtilis strains, such as QST 713, are not potent enough to effectively control fungal diseases like lettuce mildew, and existing chemical fungicides are toxic and induce resistance in pathogens, necessitating a more effective biopesticide solution.
Innovation Solution
A new Bacillus subtilis strain, IAB/BS03 (DSM 24682), with enhanced antifungal activity, is identified and used in formulations to treat plant infections, offering a potent and selective action against phytopathogenic fungi, potentially replacing synthetic chemical fungicides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic chemical fungicides are used to control plant diseases, then disease control efficacy is improved, but toxicity to wildlife and non-target species increases
Solution Approach 1:
The patent changes the fundamental parameter of the control agent from synthetic chemical compounds to biological organisms (Bacillus subtilis strains). This parameter change transforms the nature of the control mechanism, eliminating toxicity to non-target species while maintaining disease control efficacy through biological mechanisms such as antibiotic production and competition for resources.
Solution Approach 2:
The patent replaces the chemical mechanism of action with a biological mechanism. Instead of synthetic fungicides that kill pathogens through chemical toxins, the invention uses living bacterial strains that control diseases through biological interactions including production of antibacterial and antifungal substances, enzyme secretion, and direct competition with pathogenic organisms.
2Reliability
If synthetic chemical fungicides are applied repeatedly to control pathogens, then disease control is improved, but resistance development in pathogens increases
Solution Approach 1:
The patent extracts the selection pressure that drives resistance development from the control system. By using biological control agents that operate through multiple mechanisms (antibiotic production, competition, enzyme secretion) rather than a single chemical target, the system removes the selective pressure that would otherwise favor resistant pathogen strains, thereby preventing resistance development.
Solution Approach 2:
The patent changes the mode of action from chemical inhibition to biological control mechanisms. This parameter change fundamentally alters how pathogens interact with the control agent, making resistance development unlikely since the biological mechanisms are diverse and not subject to the same selective pressure as chemical fungicides.
3Adaptability or versatility
If existing Bacillus subtilis strains (e.g., QST 713) are used as biopesticides, then biological activity is improved, but potency against specific fungal diseases (e.g., lettuce mildew) remains insufficient
Solution Approach 1:
The patent applies local quality by selecting and characterizing specific strains of Bacillus subtilis that possess enhanced biological activity against particular fungal pathogens. Rather than using a generic strain, the invention identifies strains with localized expertise in controlling specific diseases such as lettuce mildew, thereby improving potency while maintaining biological versatility.
Solution Approach 2:
The patent employs copying by utilizing the well-established safety and biological activity characteristics of Bacillus subtilis while creating novel strains through selective breeding or genetic modification. This allows the invention to inherit the safe, versatile properties of the parent species while adding enhanced specificity and potency against target fungal diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IAB/BS03 strain demonstrates at least 300 times greater potency than QST 713, achieving comparable fungicidal efficacy to mancozeb + cymoxanil 4% with significantly lower doses, effectively controlling a wide range of fungal and bacterial infections.
Implementation Method 1
This activity may be due to different mechanisms of action, among which are the production of antibiotics that inhibit the development of fungi and bacteria
Implementation Method 2
Several microorganisms are known for exhibiting biological activity and are useful in plant disease control
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention relates to an isolated strain of Bacillus subtilis (IAB/BS/03) deposited at the DSM German Type Culture Collection under Access No DSM 24682, or a mutant of said strain, and also deposited at the Spanish type culture collection under Access number CECT 7254, the property of the company filing the patent, in which said strain and/or the mutant thereof exhibits antifungal and antibacterial activity, with a profile of action different from that of other strains of Bacillus subtilis and with much greater potency in terms of the capacity thereof to act as a field biological control agent. The invention also includes methods for preventing and treating fungal and bacterial diseases in plants using said bacterial strains or supernatants containing antibiotics or pure antibiotics obtained from said bacterial strains, in which said antibiotics are contained in a composition.